Design and clinical verification of surface enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction

Kevin M. Koo, Jing Wang, Renée S. Richards, Aine Farrell, John W. Yaxley, Hema Samaratunga, Patrick E. Teloken, Matthew J. Roberts, Geoffrey D. Coughlin, Martin F. Lavin, Paul N. Mainwaring, Yuling Wang, Robert A. Gardiner, Matt Trau

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The use of emerging nanotechnologies, such as plasmonic nanoparticles in diagnostic applications, potentially offers opportunities to revolutionize disease management and patient healthcare. Despite worldwide research efforts in this area, there is still a dearth of nanodiagnostics which have been successfully translated for real-world patient usage due to the predominant sole focus on assay analytical performance and lack of detailed investigations into clinical performance in human samples. In a bid to address this pressing need, we herein describe a comprehensive clinical verification of a prospective label-free surface-enhanced Raman scattering (SERS) nanodiagnostic assay for prostate cancer (PCa) risk stratification. This contribution depicts a roadmap of (1) designing a SERS assay for robust and accurate detection of clinically validated PCa RNA targets; (2) employing a relevant and proven PCa clinical biomarker model to test our nanodiagnostic assay; and (3) investigating the clinical performance on independent training (n = 80) and validation (n = 40) cohorts of PCa human patient samples. By relating the detection outcomes to gold-standard patient biopsy findings, we established a PCa risk scoring system which exhibited a clinical sensitivity and specificity of 0.87 and 0.90, respectively [area-under-curve of 0.84 (95% confidence interval: 0.81–0.87) for differentiating high- and low-risk PCa] in the validation cohort. We envision that our SERS nanodiagnostic design and clinical verification approach may aid in the individualized prediction of PCa presence and risk stratification and may overall serve as an archetypical strategy to encourage comprehensive clinical evaluation of nanodiagnostic innovations.

LanguageEnglish
Pages8362–8371
Number of pages10
JournalACS Nano
Volume12
Issue number8
DOIs
Publication statusPublished - 28 Aug 2018

Fingerprint

Raman spectroscopy
cancer
Assays
Raman scattering
predictions
Raman spectra
stratification
Biopsy
Biomarkers
Tumor Biomarkers
RNA
Nanotechnology
Gold
Labels
scoring
biomarkers
Innovation
pressing
nanotechnology
Nanoparticles

Cite this

Koo, K. M., Wang, J., Richards, R. S., Farrell, A., Yaxley, J. W., Samaratunga, H., ... Trau, M. (2018). Design and clinical verification of surface enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction. ACS Nano, 12(8), 8362–8371. https://doi.org/10.1021/acsnano.8b03698
Koo, Kevin M. ; Wang, Jing ; Richards, Renée S. ; Farrell, Aine ; Yaxley, John W. ; Samaratunga, Hema ; Teloken, Patrick E. ; Roberts, Matthew J. ; Coughlin, Geoffrey D. ; Lavin, Martin F. ; Mainwaring, Paul N. ; Wang, Yuling ; Gardiner, Robert A. ; Trau, Matt. / Design and clinical verification of surface enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction. In: ACS Nano. 2018 ; Vol. 12, No. 8. pp. 8362–8371.
@article{cddbd0aacfec4e2a8e2ef22f732bf984,
title = "Design and clinical verification of surface enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction",
abstract = "The use of emerging nanotechnologies, such as plasmonic nanoparticles in diagnostic applications, potentially offers opportunities to revolutionize disease management and patient healthcare. Despite worldwide research efforts in this area, there is still a dearth of nanodiagnostics which have been successfully translated for real-world patient usage due to the predominant sole focus on assay analytical performance and lack of detailed investigations into clinical performance in human samples. In a bid to address this pressing need, we herein describe a comprehensive clinical verification of a prospective label-free surface-enhanced Raman scattering (SERS) nanodiagnostic assay for prostate cancer (PCa) risk stratification. This contribution depicts a roadmap of (1) designing a SERS assay for robust and accurate detection of clinically validated PCa RNA targets; (2) employing a relevant and proven PCa clinical biomarker model to test our nanodiagnostic assay; and (3) investigating the clinical performance on independent training (n = 80) and validation (n = 40) cohorts of PCa human patient samples. By relating the detection outcomes to gold-standard patient biopsy findings, we established a PCa risk scoring system which exhibited a clinical sensitivity and specificity of 0.87 and 0.90, respectively [area-under-curve of 0.84 (95{\%} confidence interval: 0.81–0.87) for differentiating high- and low-risk PCa] in the validation cohort. We envision that our SERS nanodiagnostic design and clinical verification approach may aid in the individualized prediction of PCa presence and risk stratification and may overall serve as an archetypical strategy to encourage comprehensive clinical evaluation of nanodiagnostic innovations.",
author = "Koo, {Kevin M.} and Jing Wang and Richards, {Renée S.} and Aine Farrell and Yaxley, {John W.} and Hema Samaratunga and Teloken, {Patrick E.} and Roberts, {Matthew J.} and Coughlin, {Geoffrey D.} and Lavin, {Martin F.} and Mainwaring, {Paul N.} and Yuling Wang and Gardiner, {Robert A.} and Matt Trau",
year = "2018",
month = "8",
day = "28",
doi = "10.1021/acsnano.8b03698",
language = "English",
volume = "12",
pages = "8362–8371",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "8",

}

Koo, KM, Wang, J, Richards, RS, Farrell, A, Yaxley, JW, Samaratunga, H, Teloken, PE, Roberts, MJ, Coughlin, GD, Lavin, MF, Mainwaring, PN, Wang, Y, Gardiner, RA & Trau, M 2018, 'Design and clinical verification of surface enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction' ACS Nano, vol. 12, no. 8, pp. 8362–8371. https://doi.org/10.1021/acsnano.8b03698

Design and clinical verification of surface enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction. / Koo, Kevin M.; Wang, Jing; Richards, Renée S.; Farrell, Aine; Yaxley, John W.; Samaratunga, Hema; Teloken, Patrick E.; Roberts, Matthew J.; Coughlin, Geoffrey D.; Lavin, Martin F.; Mainwaring, Paul N.; Wang, Yuling; Gardiner, Robert A.; Trau, Matt.

In: ACS Nano, Vol. 12, No. 8, 28.08.2018, p. 8362–8371.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Design and clinical verification of surface enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction

AU - Koo,Kevin M.

AU - Wang,Jing

AU - Richards,Renée S.

AU - Farrell,Aine

AU - Yaxley,John W.

AU - Samaratunga,Hema

AU - Teloken,Patrick E.

AU - Roberts,Matthew J.

AU - Coughlin,Geoffrey D.

AU - Lavin,Martin F.

AU - Mainwaring,Paul N.

AU - Wang,Yuling

AU - Gardiner,Robert A.

AU - Trau,Matt

PY - 2018/8/28

Y1 - 2018/8/28

N2 - The use of emerging nanotechnologies, such as plasmonic nanoparticles in diagnostic applications, potentially offers opportunities to revolutionize disease management and patient healthcare. Despite worldwide research efforts in this area, there is still a dearth of nanodiagnostics which have been successfully translated for real-world patient usage due to the predominant sole focus on assay analytical performance and lack of detailed investigations into clinical performance in human samples. In a bid to address this pressing need, we herein describe a comprehensive clinical verification of a prospective label-free surface-enhanced Raman scattering (SERS) nanodiagnostic assay for prostate cancer (PCa) risk stratification. This contribution depicts a roadmap of (1) designing a SERS assay for robust and accurate detection of clinically validated PCa RNA targets; (2) employing a relevant and proven PCa clinical biomarker model to test our nanodiagnostic assay; and (3) investigating the clinical performance on independent training (n = 80) and validation (n = 40) cohorts of PCa human patient samples. By relating the detection outcomes to gold-standard patient biopsy findings, we established a PCa risk scoring system which exhibited a clinical sensitivity and specificity of 0.87 and 0.90, respectively [area-under-curve of 0.84 (95% confidence interval: 0.81–0.87) for differentiating high- and low-risk PCa] in the validation cohort. We envision that our SERS nanodiagnostic design and clinical verification approach may aid in the individualized prediction of PCa presence and risk stratification and may overall serve as an archetypical strategy to encourage comprehensive clinical evaluation of nanodiagnostic innovations.

AB - The use of emerging nanotechnologies, such as plasmonic nanoparticles in diagnostic applications, potentially offers opportunities to revolutionize disease management and patient healthcare. Despite worldwide research efforts in this area, there is still a dearth of nanodiagnostics which have been successfully translated for real-world patient usage due to the predominant sole focus on assay analytical performance and lack of detailed investigations into clinical performance in human samples. In a bid to address this pressing need, we herein describe a comprehensive clinical verification of a prospective label-free surface-enhanced Raman scattering (SERS) nanodiagnostic assay for prostate cancer (PCa) risk stratification. This contribution depicts a roadmap of (1) designing a SERS assay for robust and accurate detection of clinically validated PCa RNA targets; (2) employing a relevant and proven PCa clinical biomarker model to test our nanodiagnostic assay; and (3) investigating the clinical performance on independent training (n = 80) and validation (n = 40) cohorts of PCa human patient samples. By relating the detection outcomes to gold-standard patient biopsy findings, we established a PCa risk scoring system which exhibited a clinical sensitivity and specificity of 0.87 and 0.90, respectively [area-under-curve of 0.84 (95% confidence interval: 0.81–0.87) for differentiating high- and low-risk PCa] in the validation cohort. We envision that our SERS nanodiagnostic design and clinical verification approach may aid in the individualized prediction of PCa presence and risk stratification and may overall serve as an archetypical strategy to encourage comprehensive clinical evaluation of nanodiagnostic innovations.

UR - http://www.scopus.com/inward/record.url?scp=85050628496&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/arc/DP140104006

UR - http://purl.org/au-research/grants/arc/DP160102836

U2 - 10.1021/acsnano.8b03698

DO - 10.1021/acsnano.8b03698

M3 - Article

VL - 12

SP - 8362

EP - 8371

JO - ACS Nano

T2 - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 8

ER -